Previous 10 | Next 10 |
home / stock / aqszf / aqszf news
2023-05-02 09:10:50 ET Aequus Pharmaceuticals press release ( OTCQB:AQSZF ): FY GAAP EPS of -$0.02. Revenue of $1.38M (-49.1% Y/Y). For further details see: Aequus Pharmaceuticals GAAP EPS of -$0.02, revenue of $1.38M
VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing healthcare solutions to Canadians through licensing and partnerships...
VANCOUVER, British Columbia, April 19, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“ Aequus ” or the “ Company ”), announces that it has granted incentive stock options (the “Options”) to certain directors, off...
VANCOUVER, British Columbia, April 05, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today it has entered into a loan agreement to raise $500,000 to support the launch of Zimed® PF. Mr. Doug ...
VANCOUVER, British Columbia, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is pleased to announce that Health Canada has approved Zimed ® PF (Bimatoprost 0.03%) for the reduction of elevat...
VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today rep...
VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today that it has agreed to end its promotional service agreement with Sandoz Canada Inc. (“Sandoz&...
VANCOUVER, British Columbia, July 23, 2022 (GLOBE NEWSWIRE) -- Doug Janzen, of 2820 – 200 Granville St., Vancouver, BC, V6C 1S4, today announced that on Tuesday, July 19, 2022, he acquired ownership (the “ Acquisition ”) of 100,000 common shares (“ Common S...
VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) announces that further to our news release dated July 6, 2022, we will resume trading on the TSX Venture exchange tomorrow, July 14, 2022. Doug Janzen noted that ...
Aequus Pharmaceuticals ( OTCQB:AQSZF ) signed an agreement for Canadian distribution rights to 10 products of Ireland-based Scope Ophthalmics' over-the-counter ophthalmology portfolio. The products include the Optase range of preservative free dry eye products, A...
News, Short Squeeze, Breakout and More Instantly...
Aequus Pharmaceuticals Inc Company Name:
AQSZF Stock Symbol:
OTCMKTS Market:
Aequus Pharmaceuticals Inc Website:
(TheNewswire) VANCOUVER – TheNewswire - April 29, 2024 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing healthcare solutions to Canadians through lic...
(TheNewswire) Vancouver, BC - TheNewswire - November 29, 2023 - Aequus Pharmaceuticals Inc. (TSX-V:AQS ) ( OTC:AQSZF) (“ Aequus ” or the “ Company ”), a specialty pharmaceutical company with a focus on developing, a...
(TheNewswire) Vancouver, BC - TheNewswire - October 20, 2023 - Aequus Pharmaceuticals Inc. (TSX-V:AQS ) ( OTC: AQSZF) (“ Aequus ” or the “ Company ”), announces today it has increased its debt by $1,000,000 to suppo...